Division of Nephrology, University of Tennessee Health Science Center, Memphis, Tennessee USA.
Address correspondence to: L. Darryl Quarles, University of Tennessee Health Science Center, 956 Court Ave., Suite B226, Memphis, Tennessee USA. Phone: 901.448.1759; Fax: 901.448.1175; E-mail: firstname.lastname@example.org.
First published January 9, 2013 - More info
See the related Commentary beginning on page 812.
Clinical vignette: A 48-year-old man with chronic kidney disease stage five due to type II diabetes mellitus and hypertension was referred for hemodialysis initiation. His physical exam showed a blood pressure of 150/80, normal fundi, a positive fourth heart sound (S4), and trace pedal edema. Moderate aortic calcification was present on prior chest X-ray. The ECG showed left ventricle hypertrophy by voltage and slight prolongation of the QT interval. Medications included chlorthalidone, amlodipine, carvedilol, cholecalciferol, erythropoietin, and a phosphate binder. What additional therapy should be initiated to reduce vascular calcifications and cardiovascular mortality?
Cardiovascular disease (CV) is a major cause of morbidity and mortality in patients with chronic kidney disease (CKD), especially in those with end-stage renal disease (ESRD) undergoing thrice weekly hemodialysis (1). Indeed, the risk of CV-related mortality is 10- to 20-fold higher in hemodialysis patients. Interestingly, unlike the general population, in which coronary atherosclerotic disease is the principal cause of CV mortality, patients with CKD expire from chronic heart failure and sudden cardiac events. This is consistent with the fact that left ventricular hypertrophy (LVH) and vascular calcification are the most apparent cardiovascular abnormalities in patients with CKD (2). Many therapeutic strategies have failed to improve LVH, vascular calcifications, or survival in large-scale randomized controlled trials (RCTs) of patients with ESRD. Treatment with erythropoietin and statins and manipulation of hemodialysis prescription do not appear to lower mortality in ESRD (3, 4), nor do therapeutic strategies that address the mineral imbalances associated with CKD impact on CV, including vitamin D therapy (PRIMO study), calcimimetics (EVOLVE study), phosphate binders, and calcium-free phosphate binders (4–6). Small RCTs evaluating angiotensin receptor blockers (7) and the nonselective β/α1-blocker carvedilol (8) suggest that these agents may reduce cardiovascular mortality in CKD, but these conclusions need to be substantiated in larger clinical trials. Nevertheless, activation of the renin-angiotensin-aldosterone system (RAAS) may contribute to LVH and myocardial fibrosis in CKD. It is unclear how RAAS is activated in CKD.
Simplistically, hypertension and increased arterial stiffness of calcified arteries should lead to LVH; however, the pathogenesis of LVH and vascular calcifications and their relationship to mineral metabolism perturbations are proving to be complex and refractory to current treatment strategies. A new idea is that chronic elevation of the bone-derived hormone FGF23 is associated with LVH and increased CV mortality in patients with CKD (9) and links abnormalities in mineral metabolism with adverse cardiovascular outcomes. The potential mechanisms whereby FGF23 is linked to CV mortality are uncertain. There is evidence that FGF23 activates FGF receptors (FGFRs) in the myocardium to stimulate LVH (10), but this direct mechanism is controversial because α-Klotho, the FGF23 coreceptor required for FGFR activation, is not expressed in the myocardium. An equally likely possibility is that FGF23 activates FGFR/α-Klotho coreceptors in the kidney, which indirectly leads to LVH and cardiovascular mortality through activation of the RAAS. In this regard, FGF23 appears to be a potent inhibitor of ACE2 expression in the kidney (11), which prevents degradation of Ang I and Ang II. This system is further impacted by treatment with 1,25(OH)2D, which inhibits renin gene transcription and blocks RAAS but also stimulates FGF23 production in bone (12). The actions of 1,25(OH)2D to elevate circulating FGF23 levels may lead to conflicting effects on the myocardium, possibly explaining the inability of 1,25(OH)2D to improve LVH in the PRIMO study (5). Moreover, there is also evidence that Ang II suppresses renal α-Klotho expression and that α-Klotho overexpression can mitigate Ang II–induced proteinuria in experimental animal models (13).
In this issue of the JCI, Voelkl and colleagues link elevated aldosterone levels with vascular calcification and provide a mechanism for RAAS activation and subsequent LVH in CKD (14). They report that, in klotho-hypomorphic (kl/kl) mice, aldosterone directly stimulates vascular calcification by inducing PIT1-dependent phosphate transport in vascular smooth muscle cells via direct activation of the mineralocorticoid receptor. Importantly, the mineralocorticoid receptor antagonist spironolactone reduced vascular and soft tissue calcification and increased the life span in this model of α-Klotho deficiency. These findings are consistent with several prior animal studies showing that aldosterone blockade affords vascular protection and reduces vascular calcifications through blood pressure–independent mechanisms (15–17).
Vascular calcifications are known to be associated with increased mortality, presumably through development of LVH in CKD; consequently, elevations of aldosterone in a α-Klotho–deficient CKD model may also promote vascular calcification. These conclusions should be extrapolated to human CKD with some reservation. First, kl/kl mice are a model of primary loss of α-Klotho, and consequent elevations in FGF23 and 1,25(OH)2D, which likely arise from end-organ resistance to FGF23, lead to severe hyperphosphatemia and hypercalcemia. In contrast, reductions in α-Klotho in CKD are likely secondary to excess FGF23 and decreased 1,25(OH)2D, both of which are known to suppress α-Klotho expression in the kidney. Thus, the abnormalities of mineral metabolism and the mechanism of increased aldosterone may differ between kl/kl mice and models of CKD. Nevertheless, these and other studies reporting that aldosterone targets vascular smooth muscle cells to stimulate vascular calcifications (15–17) suggest that aldosterone is the proximate mediator of cardiovascular and vascular toxicity in CKD.
Mineralocorticoid receptor antagonists are standard medical therapy for patients with moderate to severe heart failure symptoms and reduced left ventricular ejection fraction and for patients with heart failure after myocardial infarction in the general population. In addition, activation of the RAAS is profibrotic, whereas inhibition of this pathway is antifibrotic for the myocardium. Therefore, should we borrow this treatment for use in ESRD to treat LVH, hypertension, and vascular calcifications? Although hyperkalemia is a concerning complication of aldosterone antagonism in the setting of CKD, studies of chronic heart failure in patients with ESRD indicate that these agents may be used with close monitoring of serum potassium levels (18–21). The long-term outcomes of combined use of ACEI, angiotensin receptor blockers, and mineralocorticoid receptor antagonists in patients with ESRD have not been evaluated in rigorous, well-designed RCTs, thus the benefits and adverse consequences of single and combination therapies in this setting are unknown. The data supporting actions of both Ang II and aldosterone to stimulate cardiac and arterial blood vessel remodeling suggest that such trials may be warranted in ESRD (22).
Should we also consider new therapies to inhibit FGF23 to reduce LVH? Before recommending such therapy it will be necessary to confirm that FGF23 directly or indirectly stimulates myocyte growth leading to LVH in CKD. It will also be important to determine at what point during the course of progressive CKD that adaptive compensatory elevations of FGF23 become maladaptive. For example, treatment of animal models of CKD with neutralizing FGF23 antibodies increased rather than decreased mortality (23). Finally, the optimal range of serum FGF23 levels needs to be determined.
There are potential strategies to reduce FGF23 in CKD. In addition to blocking antibodies, FGFR inhibitors, which are being developed as cancer therapeutics, inhibit both the production (24) and end-organ effects of FGF23 (25). Serum FGF23 concentrations can also be reduced in ESRD by treatment with cinacalcet in combination with low-dose vitamin D analogues (26). Future trials are needed to explore multifaceted interventions geared toward improving survival by targeting the proximate pathophysiological factors responsible for increased cardiovascular mortality in CKD.
L.D. Quarles is supported by NIH grants DK095812, DK083303, and AR045955. The author would like to thank Csaba P. Kovesdy and Karl T. Weber for their helpful comments.
Conflict of interest: The author is a consultant for Amgen and Cytochroma and participates in the Amgen-sponsored DesignWrite speakers bureau.
Citation for this article:J Clin Invest. 2013;123(2):542–543. doi:10.1172/JCI67203.
See the related Commentary beginning on page 812.
Copyright © 2015 American Society for Clinical Investigation